Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by Enterobacteriaceae

BMC Infectious Diseases

Nam Joong Kim²  Hyo-Suk Lee²  Myoung-don Oh²  Hong Bin Kim²  Sang Won Park²  Eu Suk Kim²  Wan Beom Park¹  Pyeong Gyun Choe²  Kyung Ho Song²  Chung Jong Kim²  Shinhye Cheon²  Younghee Jung²  Ji Hwan Bang¹ 

[1] Division of Infectious Diseases, Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Republic of Korea;Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, Seoul, 110-744, Republic of Korea

关键词: Liver cirrhosis;    Bacteremia;    Pseudomonas aeruginosa;   

Others  :  1146927
DOI  :  10.1186/1471-2334-13-332

 received in 2013-03-11, accepted in 2013-07-17,  发布年份 2013

【 摘 要 】

Background

This study was performed to detect risk factors for Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis.

Methods

A retrospective case–control study was designed to identify risk factors for P. aeruginosa bacteremia in cirrhotic patients. The cases were cirrhotic patients with P. aeruginosa bacteremia and the controls were cirrhotic patients with Enterobacteriaceae bacteremia.

Results

Sixty-one cases and the same number of controls were enrolled. In a multivariate analysis, younger age {adjusted odds ratio (aOR) per one year: 0.96, 95% confidence interval: 0.93 - 0.99}, nosocomial acquisition (aOR 3.87, 95% confidence interval: 1.50 - 9.94), preexisting biliary disease (aOR 4.79, 95% confidence interval: 1.92 - 10.47), and recent exposure to immunosuppressive agent (aOR 3.10, 95% confidence interval: 1.23 - 7.82) were associated with P. aeruginosa bacteremia. In the case group the frequency of appropriate initial antibiotic regimens was considerably lower than in the control group: 29.5% vs. 65.6% (P <0.01). However, thirty day mortality did not differ significantly between cases and controls (19.7% vs. 24.6%).

Conclusions

Nosocomial acquisition, preexisting biliary disease, and recent use of immunosuppressive agents are strong predictive factors for P. aeruginosa bacteremia in cirrhotic patients.

【 授权许可】

   
2013 Bang et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, Rodes J: Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002, 35:140-148.
• [2]Foreman MG, Mannino DM, Moss M: Cirrhosis as a risk factor for sepsis and death: analysis of the national hospital discharge survey. Chest 2003, 124:1016-1020.
• [3]Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R: Severe sepsis in cirrhosis. Hepatology (Baltimore, Md) 2009, 50:2022-2033.
• [4]Thulstrup AM, Sorensen HT, Schonheyder HC, Moller JK, Tage-Jensen U: Population-based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis. Clin Infect Dis 2000, 31:1357-1361.
• [5]Linderoth G, Jepsen P, Schonheyder HC, Johnsen SP, Sorensen HT: Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: a population-based cohort study. Alcohol Clin Exp Res 2006, 30:636-641.
• [6]Vidal F, Mensa J, Almela M, Martinez JA, Marco F, Casals C, Gatell JM, Soriano E, Jimenez de Anta MT: Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. analysis of 189 episodes. Arch Intern Med 1996, 156:2121-2126.
• [7]Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW: Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003, 37:745-751.
• [8]Bisbe J, Gatell JM, Puig J, Mallolas J, Martinez JA, Soriano E, Jimenez de Anta MT: Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis 1988, 10:629-635.
• [9]Kuikka A, Valtonen VV: Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998, 17:701-708.
• [10]Gransden WR, Leibovici L, Eykyn SJ, Pitlik SD, Samra Z, Konisberger H, Drucker M, Phillips I: Risk factors and a clinical index for diagnosis of Pseudomonas aeruginosa bacteremia. Clin Microbiol Infect 1995, 1:119-123.
• [11]Joo EJ, Kang CI, Ha YE, Kim J, Kang SJ, Park SY, Lee NY, Wi YM, Chung DR, Peck KR, Song JH: Clinical predictors of Pseudomonas aeruginosa bacteremia among Gram-negative bacterial infections in non-neutropenic patients with solid tumor. J Infect 2011, 63:207-214.
• [12]Cheong HS, Kang CI, Wi YM, Ko KS, Chung DR, Lee NY, Song JH, Peck KR: Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia. Eur J Clin Microbiol Infect Dis 2008, 27:1219-1225.
• [13]Schechner V, Nobre V, Kaye KS, Leshno M, Giladi M, Rohner P, Harbarth S, Anderson DJ, Karchmer AW, Schwaber MJ, Carmeli Y: Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin Infect Dis 2009, 48:580-586.
• [14]Pier GB, Ramphal R: Pseudomonas aeruginosa. In Principles and practice of infectious diseases. Volume 2. 7th edition. Edited by Mandell GM, Bennett JE, Dolin R. Philadelphia, PA, the Unites States: Churchill Livingsone; 2010:2835-2860.
• [15]Vuotto F, Berthon C, Lemaitre N, Duhamel A, Balkaran S, Le Ray E, Micol JB, Faure K, Alfandari S: Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case–control study. Am J Infect Controlin press
• [16]Cheong HS, Kang CI, Wi YM, Kim ES, Lee JS, Ko KS, Chung DR, Lee NY, Song JH, Peck KR: Clinical significance and predictors of community-onset Pseudomonas aeruginosa bacteremia. Am J Med 2008, 121:709-714.
• [17]Kang CI, Sung YK, Lee KH, Lee KT, Lee JK: Clinical impact of inappropriate initial antimicrobial therapy on outcome in bacteremic biliary tract infections. Scand J Infect Dis 2013, 45:227-234.
• [18]Kwon W, Jang JY, Kim EC, Park JW, Han IW, Kang MJ, Kim SW: Changing trend in bile microbiology and antibiotic susceptibilities: over 12 years of experience. Infection 2013, 41:93-102.
• [19]Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Lopez J, Pitart C, Mensa J: Epidemiology and prognostic determinants of bacteraemic biliary tract infection. J Antimicrob Chemother 2012, 67:1508-1513.
• [20]Hoiby N, Kharazmi A, Ciofu O, Song Z, Moser C, Krogh Johansen H: Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001, 3:23-35.
• [21]Mann EE, Wozniak DJ: Pseudomonas biofilm matrix composition and niche biology. FEMS Microbiol Rev 2012, 36:893-916.
• [22]Szabo S, Mendelson MH, Mitty HA, Bruckner HW, Hirschman SZ: Infections associated with transhepatic biliary drainage devices. Am J Med 1987, 82:921-926.
• [23]Struelens MJ, Rost F, Deplano A, Maas A, Schwam V, Serruys E, Cremer M: Pseudomonas aeruginosa and Enterobacteriaceae bacteremia after biliary endoscopy: an outbreak investigation using DNA macrorestriction analysis. Am J Med 1993, 95:489-498.
• [24]Chen SC, Lawrence RH, Byth K, Sorrell TC: Pseudomonas aeruginosa bacteraemia. Is pancreatobiliary disease a risk factor? The Medical journal of Australia 1993, 159:592-597.
• [25]Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH: Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005, 49:1306-1311.
• [26]Sifuentes-Osornio J, Gonzalez R, Ponce-de-Leon A, Guerrero ML: Epidemiology and prognosis of Pseudomonas aeruginosa bacteremia in a tertiary care center. Rev Invest Clin 1998, 50:383-388.